8-K: Anteris Initiates Global Pivotal Trial for DurAVR THV

Anteris Technologies announced the successful enrollment and treatment of the first patients in its global pivotal PARADIGM Trial for the DurAVR Transcatheter Heart Valve.

Summary

• Anteris Technologies Global Corp. has initiated its global pivotal PARADIGM Trial for the DurAVR Transcatheter Heart Valve (THV) for patients with severe calcific aortic stenosis.
• The first patients have been successfully enrolled and treated in the trial.
• Procedures were performed by Prof. Dr. Ole De Backer at The Heart Center, Rigshospitalet, Copenhagen University Hospital, Denmark.
• The PARADIGM Trial is a prospective randomized controlled trial (RCT) evaluating the safety and effectiveness of DurAVR THV compared to commercially available transcatheter aortic valve replacements (TAVRs).
• The study will enroll approximately 1,000 patients in an 'All Comers Randomized Cohort' with a 1:1 randomization.
• The primary composite endpoint for non-inferiority assessment includes all-cause mortality, all stroke, and cardiovascular hospitalization at one year post-procedure.
• The trial builds on existing clinical data from 130 patients successfully treated with DurAVR THV, including de novo, valve-in-valve, and complex anatomies.
• Anteris plans to expand the PARADIGM Trial to additional countries and sites in the near term, including the United States, Europe, and Canada.

Sentiment

Score: 8

Explanation: The announcement is highly positive, marking a significant advancement in the company's lead product development. The initiation of a global pivotal trial, especially a head-to-head study, is a major de-risking event and a critical step towards commercialization. The positive initial experience and the robust trial design contribute to a strong positive sentiment.

Positives

• Successful enrollment and treatment of the first patients in the global pivotal PARADIGM Trial marks a significant milestone for the DurAVR THV.
• Initial experience with the DurAVR THV System has been very positive, according to Prof. Dr. Ole De Backer.
• The head-to-head study design against commercially available TAVRs is expected to provide robust comparative evidence across all surgical risk groups, potentially differentiating the DurAVR platform based on efficacy, safety, and ease of use.
• The DurAVR THV is described as the first biomimetic valve, designed to mimic healthy human aortic valve performance and replicate normal aortic blood flow.
• The ADAPT tissue used in DurAVR THV is FDA-cleared, has over 10 years of clinical use, and has been distributed for use in over 55,000 patients worldwide.

Risks

• Forward-looking statements regarding the planned expansion, results, and commercialization of the PARADIGM Trial are subject to a number of risks, uncertainties, and assumptions.
• Specific risks are described under 'Risk Factors' in Anteris' Annual Report on Form 10-K for the fiscal period ended December 31, 2024, filed with the SEC and ASX.

Future Outlook

Management anticipates efficient recruitment and timely study advancement due to strong investigator enthusiasm. The company aims to drive the global PARADIGM Trial through expansion across the United States, Europe, and Canada, with additional cohorts planned. The trial is expected to generate clinical evidence required to advance DurAVR THV toward commercialization and expand treatment options for aortic stenosis patients.

Management Comments

• Prof. Dr. Ole De Backer stated, "We are proud to be the first enrolling center for this important trial... Our initial experience with the DurAVR THV System has been very positive, and we look forward to providing definitive comparative evidence which could transform patient care."
• Chris Meduri, M.D., Anteris Chief Medical Officer, commented, "With the first patients now randomized in the PARADIGM Trial, we are actively generating the clinical evidence required to advance the DurAVR THV toward commercialisation, expanding treatment options for aortic stenosis patients... This head-to-head study will provide robust comparative evidence across all surgical risk groups, which we believe will differentiate our platform based on efficacy, safety and ease of use."

Industry Context

This announcement positions Anteris Technologies as a key player in the structural heart market, specifically in the treatment of aortic stenosis. The initiation of a global pivotal trial for a novel transcatheter heart valve (THV) indicates a move towards challenging established TAVR technologies. The 'head-to-head' study design suggests a direct competitive strategy, aiming to demonstrate superior or non-inferior outcomes against existing commercial devices, which is crucial for market penetration in a competitive landscape dominated by major medical device companies.

Comparison to Industry Standards

• The PARADIGM Trial is a prospective randomized controlled trial (RCT), considered Level 1 evidence, the highest level for determining effectiveness in evidence-based medicine, aligning with rigorous industry standards for medical device approvals.
• The trial is a 'head-to-head' study comparing DurAVR THV to 'commercially available transcatheter aortic valve replacements (TAVRs)', directly challenging established products from competitors like Medtronic (e.g., Evolut) and Edwards Lifesciences (e.g., SAPIEN).
• The primary composite endpoint of all-cause mortality, all stroke, and cardiovascular hospitalization at one year post-procedure is a standard and comprehensive measure used in TAVR trials to assess safety and effectiveness against global benchmarks.
• The enrollment of approximately 1,000 patients in an 'All Comers Randomized Cohort' is a substantial sample size, comparable to pivotal trials for other leading TAVR devices, ensuring statistical power for robust comparative evidence.

Stakeholder Impact

• **Shareholders**: Positive impact due to the significant progress in the development of the company's lead product, potentially increasing future revenue streams and market value. The initiation of a pivotal trial is a key de-risking event.
• **Patients with Aortic Stenosis**: Potential for an expanded and improved treatment option with a biomimetic valve designed to replicate normal aortic blood flow, offering better long-term outcomes.
• **Medical Professionals (Cardiologists, Surgeons)**: Provides a new, potentially differentiated device for treating aortic stenosis, supported by a robust head-to-head clinical trial, which could transform patient care.
• **Competitors**: Increased competition in the TAVR market, particularly from a device aiming to differentiate itself based on efficacy, safety, and ease of use through a direct comparative study.

Next Steps

• Actively generating clinical evidence required to advance DurAVR THV toward commercialization.
• Expanding the PARADIGM Trial across the United States, Europe, and Canada.
• Adding further countries and sites to the global PARADIGM Trial in the near term.
• Recruiting approximately 1,000 patients for the 'All Comers Randomized Cohort'.

Key Dates

Recommendation

The initiation of a global pivotal trial for a lead product, especially a head-to-head study against established competitors, is a significant de-risking event for a medical device company. The positive initial experience and the robust trial design provide a strong foundation for future commercial success. This milestone suggests the company is progressing well towards market entry, which typically warrants a 'buy' recommendation for investors looking for growth in the medical technology sector, assuming the trial continues to show positive results and the company manages its financial resources effectively.

Keywords

Anteris Technologies, DurAVR THV, PARADIGM Trial, Transcatheter Heart Valve, Aortic Stenosis, Medical Devices, Clinical Trial, Structural Heart, ADAPT tissue, TAVR